March 15, 2021 -- Sanofi Pasteur, the vaccine unit of Sanofi, is partnering with Translate Bio on a phase I/II clinical trial for MRT5500, a messenger RNA (mRNA) vaccine candidate against SARS-CoV-2. The firms expect interim results in the third quarter of 2021.
A total of 415 healthy adults 18 years and older are expected to be enrolled in the trial across 13 investigational sites. Participants will receive one dose of MRT5500 or two doses 21 days apart at the dose levels of 15 µg, 45 µg, or 135 µg. Preclinical studies to assess efficacy against emerging SARS-CoV-2 variants will continue for the next several months, according to the firms.
Additionally, a joint development team is working to improve MRT5500's temperature stability, aiming for a -20° C storage temperature for late-stage clinical trials and at the vaccine's launch. The firms are also striving for stability at routine refrigerator temperatures (2° C to 8° C).
Copyright © 2021 scienceboard.net